**GHSC-PSM-TO2-2019-MALARIA\_PHARMACEUTICAL-EOI**

**Annex 8 – Semi-Synthetic Artemisinin (SSA) Access Questionnaire**

GHSC-PSM, in coordination with the President’s Malaria Initiative (PMI) and The Global Fund Against AIDS, Tuberculosis and Malaria (GFATM), seeks to ensure a continued and consistent supply of artemisinin, a key starting material for many malaria pharmaceutical products. Long term agreements with pre-approved sources of artemisinin are one method for supporting that objective. Consistent, affordable sources of quality assured semi-synthetic artemisinin will also support sustained access to non-seasonal, and affordable artemisinin. This will then, in turn, contribute to stabilizing prices for patients and the donor community.

All manufacturers responding to this EOI, with offers of products containing artemisinin, are required to provide a completed SSA Access Questionnaire detailing their current and/or near-term business plan for continued access to artemisinin through agreements with SSA providers.

In alignment with this requirement, please describe your current / planned capabilities and experience per the questions below (not to exceed 1 page).

**1.Does your organization currently produce finished pharmaceutical product (FPP) for sale utilizing SSA?**

**2.Does your organization currently utilize SSA in at least 25 percent of production?**

**3.Does your organization use SSA in the production of any of the products specified in its submission for this EOI, if so, which product(s)?**

**4. If your answer to the above question is no, please describe the steps and time required for your company to reach this objective, including major milestones such as supply agreement for SSA executed; plan for current stock of natural artemisinin; changes in manufacturing process or packaging; etc.**